Most Cited Articles of Progression-free survival

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)European Journal of Cancer200916.1K
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of CanadaJournal of the National Cancer Institute200013.6K
Improved survival with ipilimumab in patients with metastatic melanomaNew England Journal of Medicine201010.6K
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancerNew England Journal of Medicine20048.5K
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaNew England Journal of Medicine20096.3K
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung CancerNew England Journal of Medicine20156K
Improved survival with vemurafenib in melanoma with BRAF V600E mutationNew England Journal of Medicine20115.9K
PD-1 Blockade in Tumors with Mismatch-Repair DeficiencyNew England Journal of Medicine20155.6K
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung CancerNew England Journal of Medicine20155.5K
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung CancerNew England Journal of Medicine20165.4K
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialLancet Oncology, The20095.1K
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaNew England Journal of Medicine20155K
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancerScience20155K
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancerNew England Journal of Medicine20064.8K
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancerNew England Journal of Medicine20114.7K
Sunitinib versus interferon alfa in metastatic renal-cell carcinomaNew England Journal of Medicine20074.7K
Erlotinib in previously treated non-small-cell lung cancerNew England Journal of Medicine20054.6K
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialLancet, The20104.6K
Human papillomavirus and survival of patients with oropharyngeal cancerNew England Journal of Medicine20104.4K
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFRNew England Journal of Medicine20104.2K
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancerNew England Journal of Medicine20064.1K
Sorafenib in advanced clear-cell renal-cell carcinomaNew England Journal of Medicine20074K
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialLancet Oncology, The20124K
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialLancet, The20164K
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neckNew England Journal of Medicine20064K